Inhalation Sciences secures important IP rights
(Stockholm 29 October, 2020) Swedish medtech innovator Inhalation Sciences Sweden AB (publ), forerunner in the development of next-generation labtech equipment for inhalation research, secures important IP rights for its state-of-the-art laboratory system PreciseInhale®. The unique system allows scientists to work with several different preclinical services based on PreciseInhale and measure how inhaled particles act in our lungs and affect our health.
Inhalation Sciences Sweden AB reports the following IP-related events.
Important patent secured in the US for PreciseInhale®
Today’s standard technologies for scientists, helping them measure how inhaled particles act in our lungs and affect our health, are imprecise and largely unchanged since the 1950’s. PreciseInhale® sets a completely new standard as it delivers results with a proven high correlation between laboratory in vitro testing, and animal exposure, and soon also to human testing – enabling more cost-efficient medicines for a large variety of accelerating global killer diseases of the respiratory tract.
Inhalation Sciences now reports that the US patent office has issued a notice on October 20, 2020, that a US Patent will be granted based on the application 14/906,701. The US Patent will cover the unique aerosol generating technology used in PreciseInhale. Patents to this key element of PreciseInhale have previously been granted in the major EU markets, such as the UK, France and Germany. Together with other patents, Inhalation Sciences has now increased the possibility of controlling future market expansion for the product PreciseInhale.
CEO Manoush Masarrat: “This new patent is of vital strategic importance for us. Following our recently approved new patent for ‘regional targeting’, it is yet further proof of how we continue to be the leading innovators in aerosol and inhalation R&D, a fast-growing and ever more urgent market.”
Lucrative market opportunities
The global respiratory care devices market is expected to grow from USD 21 billion in 2019 and to reach USD 40 billion by 2027*. The growth can mainly be attributed to the high prevalence of respiratory diseases, a rising aging population across the globe, high prevalence of smoking, constantly increasing pollution levels, increasing incidence of preterm births, and lifestyle changes. Also, a lack of awareness in respiratory care is leading to an underdiagnosed and undertreated population.
*Fior Markets report 417943 on Medical Devices
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush Masarrat@inhalation.se
Telephone: +46 (0)736 289 153
About Inhalation Sciences Sweden AB
Inhalation Sciences develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.
Inhalation Sciences shares are traded on the Spotlight Stock Market (ticker: ISAB). To find out more about Inhalation Sciences please visit www.inhalation.se.
Tags: